Form 8-K - Current report:
SEC Accession No. 0001213900-25-060349
Filing Date
2025-07-01
Accepted
2025-07-01 16:00:24
Documents
12
Period of Report
2025-06-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea024660801-8k_emmaus.htm   iXBRL 8-K 25402
  Complete submission text file 0001213900-25-060349.txt   185716

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE emma-20250630.xsd EX-101.SCH 3029
3 XBRL LABEL FILE emma-20250630_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE emma-20250630_pre.xml EX-101.PRE 22368
14 EXTRACTED XBRL INSTANCE DOCUMENT ea024660801-8k_emmaus_htm.xml XML 3359
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

EIN.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 251096169
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)